Suggested remit: To appraise the clinical and cost effectiveness of treatments for renal cell carcinoma (RCC).
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information Scoping commencing
Process Pathways Pilot
ID number 6186

Project Team

Project lead Jeremy Powell

Email enquiries

External Assessment Group Peninsula Technology Assessment Group (PenTAG), University of Exeter

Stakeholders

Companies sponsors Ipsen (cabozantinib)
Others Department of Health and Social Care
  NHS England
Patient carer groups Action Kidney Cancer
  Kidney Cancer UK
Professional groups Association of Cancer Physicians
  British Association of Urological Surgeons
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
  UK Kidney Association
Comparator companies Accord Healthcare (sunitinib) (not participating)
  BMS (ipilimumab, nivolumab)
  Dr Reddy’s Laboratories (sunitinib) (not participating)
  Eisai (lenvatinib)
  Eusa Pharma (tivozanib) (not participating)
  Merck Sharp & Dohme (pembrolizumab)
  Mylan (sunitinib) (not participating)
  Novartis (pazopanib)
  Piramal Critical Care (sunitinib) (not participating)
  Pfizer (sunitinib) (not participating)
  Sandoz (sunitinib)
  Teva UK (sunitinib) (not participating)
  Zentiva (sunitinib) (not participating)
  Pathway companies:
  Accord Healthcare (sunitinib, everolimus) (not participating)
  BMS (ipilimumab, nivolumab)
  Dr Reddy’s Laboratories (sunitinib, everolimus) (not participating)
  Eisai (lenvatinib)
  Eusa Pharma (tivozanib) (not participating)
  Ethypharm UK (everolimus) (not participating)
  Ipsen (cabozantinib)
  Merck Serono (avelumab)
  Merck Sharp & Dohme (pembrolizumab)
  Mylan (sunitinib) (not participating)
  Novartis (everolimus, pazopanib)
  Piramal Critical Care (sunitinib) (not participating)
  Pfizer (axitinib, sunitinib) (not participating)
  Sandoz (everolimus, sunitinib)
  Teva UK (sunitinib) (not participating)
  Zentiva (sunitinib) (not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
01 February 2024 Committee meeting: 2
30 November 2023 This appraisal has been developed as part of NICE's proportionate approach to technology appraisals. It is a pilot for the ‘Pathways’ approach. Further documents are published under cabozantinib with nivolumab for untreated advanced renal cell carcinoma [ID6184].
26 October 2023 Committee meeting: 1
24 April 2023 Assessment report sent for information
13 February 2023 Please note that belzutifan will not be included in the renal cell carcinoma pathways evaluation at this time. NICE and the company are continuing to liaise about scheduling for this topic and further participation in the pathway evaluations.
13 February 2023 Invitation to participate
16 January 2023 (13:00) Scoping workshop
21 November 2022 - 19 December 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
21 November 2022 In progress

For further information on our processes and methods, please see our CHTE processes and methods manual